

ASX RELEASE

Volpara Quarterly Results and Investor Conference Call

Wellington, NZ, 18 April 2018: [Volpara Health Technologies](#) (“Volpara”; ASX: VHT), a digital health company focused on early detection of breast cancer through improving quality of screening using artificial intelligence (AI), is pleased to advise it will release its Appendix 4C – Quarterly Cash Flow Statement for the period ended 31 March 2018 (Q4 FY18) on 30 April 2018.

Investors are invited to join a conference call hosted by CEO, Dr Ralph Highnam, CFO Craig Hadfield and CCO Mark Koeniguer at 9am AEST (11am NZST) Monday 30 April 2018.

To pre-register, please follow this link:

<https://services.choruscall.com.au/diamondpass/volpara-815488-invite.html>

You will receive a calendar notification with dial-in details and PIN for fast-track access to the call.

ENDS.

About Volpara Health Technologies Limited (ASX: VHT)

Founded in 2009 from research originally conducted at Oxford University, VHT is based in Wellington, New Zealand, and is a digital health company focused on the early detection of breast cancer by improving quality of screening using artificial intelligence. Its clinical support software provides real-time feedback on breast density, compression, dose and quality, while its enterprise-wide software, VolparaEnterprise, assists breast clinics to more efficiently manage their business by providing a centralized overview and wide-ranging benchmarking.

VHT has a number of patents and trademarks and regulatory clearances, including FDA and CE Mark, supporting its technology and services. An ASX-listed company that raised A\$20M through an IPO and subsequent share placement and rights issue in 2016, VHT has customers and/or research projects in 36 countries.

VHT uses the following definitions:

- Total Contract Value (TCV)—the value of contracts signed in the specified period. The revenue from these deals might be recognised over one or many years, and the customer might or might not have a cancellation clause of some kind.
- Annual Recurring Revenue (ARR) —the normalized amount of cash reasonably expected to be booked for the next 12 months based on the contracts signed previously, and assuming installation upon order.

www.volparasolutions.com

For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparasolutions.com
t: +64 21 149 0541

Scott Newstead
WE Buchan
snewstead@we-buchan.com
t: +61 3 9866 4722